Scopio Labs

Scopio Labs has designed and built a computational microscope and developed a proprietary diagnostics platform to enable quality microscopic analysis, with the aim of providing easy and wide access to microscopy. By merging hardware and software, the companys ultimate goal is to provide better diagnostics for everyone. Scopio Labs smart digitized system bolsters manual examination by automating the majority of the screening process. It automatically scans the relevant area of the slide, preclassifies cells, and prepares the information for quick review in order to increase efficiency and connectivity while reducing the effects of human error. The digital microscopy solution is designed to improve overall usability, produce a platform accessible to all labs, and increase accuracy and connectivity by capturing the entire sample as opposed to individual cells. The Full-Field Peripheral Blood Smear Application on the X100 is the first end-to-end digital solution that offers full-field imaging and an AI-powered Decision Support System (DSS) with remote connectivity through your secure hospital network. The Full-Field Peripheral Blood Smear Application (FF-PBS) on the X100 is FDA Cleared and CE Marked.

Scopio Labs has raised $126.76M in total funding across 8 rounds. The company is currently at the D stage. Key investors include Viola Growth, Fortissimo Capital, Aescuvest.

Scopio Labs was founded in 2014 by Itai Hayut (Co-founder & CEO), Erez Naaman (Co-founder & CTO).

Scopio Labs operates in Health Tech & Life Sciences, Digital Healthcare, Digital Medical Diagnostics, with core technologies in Platforms & Interfaces, Software, Artificial Intelligence, Computer Vision, Machine Learning. Target customers: Healthcare & Life Sciences, Healthcare, Providers, Laboratories.

Scopio Labs is based in HaSharon St 10, Tel Aviv-Yafo, Israel, Center District. The company also has offices abroad.